Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT ID: NCT00030446

Last Updated: 2020-04-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-01-10
• Study Completion Date: 2009-12-21

Brief Summary

RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with carboplatin may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining erlotinib and carboplatin in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Detailed Description

OBJECTIVES:

• Determine the response rate in patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer treated with erlotinib and carboplatin.
• Determine the duration of stable disease, time to progression, and response duration in patients treated with this regimen.
• Determine the toxicity of this regimen in these patients.
• Correlate the level of epidermal growth factor receptor tumor expression with objective tumor response in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified according to response to prior platinum-containing therapy (platinum-sensitive, defined as 6 months or more since prior therapy with platinum agent [closed to accrual as of 2/13/2004], vs platinum-resistant, defined as less than 6 months since prior therapy with platinum agent).

Patients receive carboplatin IV over 30 minutes on day 1 and oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. After the completion of 6 courses of therapy, patients with responsive or stable disease may continue to receive erlotinib and carboplatin in the absence of disease progression or unacceptable toxicity.

Patients are followed at 4 weeks and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 23-60 patients (8-30 for platinum-sensitive stratum [closed to accrual as of 2/13/2004] and 15-30 for platinum-resistant stratum) will be accrued for this study within 15-23 months.

Conditions

Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

carboplatin

Intervention Type: DRUG

erlotinib hydrochloride

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer for which no standard curative therapy exists
• At least 1 measurable lesion

• At least 20 mm by x-ray, non-spiral CT scan, or physical exam OR at least 10 mm by spiral CT scan
• Ascites and bone metastases not considered measurable disease
• No abdominal adenocarcinoma of unknown origin or borderline ovarian tumor
• No elevated CA 125 as only evidence of disease
• At least 1 but no more than 2 prior chemotherapy regimens required

• First regimen must have contained cisplatin or carboplatin
• Switching platinum compounds due to disease progression or failure to respond is considered 2 regimens
• Same regimen as first- and second-line therapy is considered 2 regimens
• Responded to prior platinum-based first-line chemotherapy

• No platinum-refractory disease
• No known brain metastases

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 12 weeks

Hematopoietic:

• Absolute granulocyte count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3

Hepatic:

• Bilirubin no greater than upper limit of normal (ULN)
• AST/ALT no greater than 2.5 times ULN

Renal:

• Creatinine no greater than ULN

Cardiovascular:

• No symptomatic congestive heart failure
• No unstable angina
• No cardiac arrhythmia

Gastrointestinal:

• See Surgery
• No GI tract disease resulting in an inability to take oral medication or requiring IV alimentation
• No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)
• No active peptic ulcer disease

Ophthalmic:

• No ocular inflammation or infection
• No significant ophthalmologic abnormalities, including:

• History of dry eye syndrome, Sjögren's syndrome, or keratoconjunctivitis sicca
• Severe exposure keratopathy
• Disorders that might increase the risk for epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)
• Congenital abnormality (e.g., Fuch's dystrophy)
• Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
• Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior allergic reaction to compounds of similar chemical or biological composition to erlotinib
• No other serious illness, medical condition, or significant neurologic or psychiatric disorder that would preclude study therapy
• No active uncontrolled infection
• No grade 3 or greater drug-related neurotoxicity
• No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)

Endocrine therapy:

• Not specified

Radiotherapy:

• At least 4 weeks since prior radiotherapy (except low-dose palliative radiotherapy) and recovered

Surgery:

• At least 3 weeks since prior major surgery (wound healing must have occurred)
• No prior surgical procedures affecting gastrointestinal (GI) absorption
• No concurrent ophthalmic surgery

Other:

• No prior therapy targeting epidermal growth factor receptor
• No other concurrent anticancer therapy
• No other concurrent investigational agents
• Concurrent oral anticoagulants (e.g., warfarin) allowed provided INR is monitored

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

NCIC Clinical Trials Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hal W. Hirte, MD, FRCP(C)

Role: STUDY_CHAIR

Margaret and Charles Juravinski Cancer Centre

Locations

Tom Baker Cancer Center - Calgary

Calgary, Alberta, Canada

British Columbia Cancer Agency - Centre for the Southern Interior

Kelowna, British Columbia, Canada

British Columbia Cancer Agency

Vancouver, British Columbia, Canada

Queen Elizabeth II Health Science Centre

Halifax, Nova Scotia, Canada

Margaret and Charles Juravinski Cancer Centre

Hamilton, Ontario, Canada

Cancer Care Ontario-London Regional Cancer Centre

London, Ontario, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Hopital Notre- Dame du CHUM

Montreal, Quebec, Canada

Countries

Canada

References

Hirte H, Oza A, Hoskins P, et al.: Phase II study of OSI-774 given in combination with carboplatin in patients (pts) with recurrent epithelial ovarian cancer (EOC): NCIC CTG IND.149. [Abstract] European Journal of Cancer Supplements 1 (5): A-159, S51, 2003.

Reference Type: RESULT

Other Identifiers

CAN-NCIC-149

Identifier Type: OTHER

Identifier Source: secondary_id

CDR0000069166

Identifier Type: OTHER

Identifier Source: secondary_id

I149

Identifier Type: -

Identifier Source: org_study_id